Trial Profile

A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 22 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KUP 101 (Primary)
Indications Basal cell cancer; Carcinoma; Malignant melanoma; Merkel cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Kupando

Most Recent Events

18 Mar 2026 According to Kupando media release, company secures additional 10 Million EUROs in Series A Financing to support this Phase 1b clinical study of KUP101 in advanced solid tumors.
01 Dec 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com